News und Analysen
PerkinElmer Changes COVID-19 Rapid Testing Landscape with Highly Sensitive Point of Care Antigen Test for Mass Screening
PerkinElmer, Inc. (NYSE: PKI) today announced the launch of the PerkinElmer® COVID-19 Antigen Test for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigen in nasal (NS) or
Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC)
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Angela Hwang, Group President, Pfizer Biopharmaceuticals Group, at the Cowen 41st Annual
PerkinElmer Provides an Update on Valencia Branch Laboratory’s Accreditation Process
PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today provided an update on the COVID-19 Valencia Branch Laboratory’s (VBL) accreditation process. The
Illumina and the University Hospital of Tübingen Evaluate Potential of Whole Genome Sequencing to Improve Diagnosis of Full Range of Genetic Diseases
February 19, 2021 -- Illumina, Inc. (Nasdaq: ILMN) today announced an agreement with the Institute of Medical Genetics and Applied Genomics at the University Hospital of Tübingen to assess the
Agilent Ranks No. 2 on Barron’s List of America’s Most Sustainable Companies
Agilent Technologies Inc. (NYSE: A) has earned the number two position on Barron’s annual list of America’s Most Sustainable Companies. The ranking marks the third straight year Agilent has been
Agilent Announces Immunoassay Kit to Detect SARS-CoV-2 Antibodies
Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit intended for the qualitative detection of
Humana Launches Humana Care Support Pilot to Help Medicare Advantage Members to Better Manage Their Chronic Conditions
Humana Inc. (NYSE: HUM) recently launched a pilot for its new Humana Care Support, formerly known as the Enterprise Clinical Operating Model (ECOM), to help support a select group of Medicare
Agilent Announces Higher-Sensitivity XF Analysis Solution for Low Abundant Immune Cell Metabolic Analysis
Agilent Technologies Inc. (NYSE: A) today introduced the Agilent Seahorse XF HS Miniplate designed specifically for the Agilent Seahorse XF HS Mini Analyzer for improved immune cell metabolic
Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma
Pfizer Inc. (NYSE:PFE) today announced that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study (NCT04649359) of elranatamab (PF-06863135), an
Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the European Commission (EC) to supply an additional 200 million doses of COMIRNATY®, the companies’
Agilent Reports First-Quarter Fiscal Year 2021 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.55 billion for the first quarter ended Jan. 31, 2021, an increase of 14% compared to the first quarter of 2020 and up 11% on a core(
PerkinElmer to Present at Cowen Health Care Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the 41st Annual Cowen Health Care Conference on
U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for PANZYGA® (Immune Globulin Intravenous
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2020
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2020.
Record fourth quarter revenue reflects a strong close to 2020:
-
Revenue of $953
Humana and IBM Watson Health Collaborate to Simplify and Enhance the Member Experience for Humana Employer Group Customers
Humana Inc. (NYSE: HUM) and IBM (NYSE: IBM) Watson Health today announced a collaboration leveraging IBM’s conversational artificial intelligence (AI) solution – to help provide a better member
Humana Begins Coverage of Hospice Services as Part of Medicare Demonstration
Humana Inc. (NYSE: HUM) has begun evaluating a new way of offering hospice services to members of select Medicare Advantage plans in an attempt to provide greater continuity of care, additional
Waters Redefines Laboratory Science with New ACQUITY PREMIER Liquid Chromatography Solution
Waters Corporation (NYSE:WAT) today introduced the Waters™ ACQUITY™ PREMIER Solution, the next generation in liquid chromatographs featuring Waters’ breakthrough MaxPeak™ High Performance Surface
Illumina to Webcast Upcoming Investor Conference Presentations
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.
SVB Leerink Annual Global
Agilent to Present at Upcoming Investor Events; Provides Webcast Details for Annual Shareholder Meeting
Agilent Technologies Inc. (NYSE: A) today announced the following webcasts for the investment community.
10th Annual SVB Leerink Global Healthcare Conference
Wednesday, Feb. 24 at 7:40 a.m
Illumina Accelerator Invests in Nine Genomics Startups for Second Global Cycle
Feb. 8, 2021 -- Illumina, Inc. (NASDAQ: ILMN) has selected nine new genomics companies to join the second global funding cycle of Illumina Accelerator in the U.S. and UK. The global company
Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Patent and Trademark Office (USPTO) recently issued a U.S. Patent Term Extension (PTE) certificate for IBRANCE® (palbociclib). The certificate
Illumina Supports National Program to Evaluate Potential of Comprehensive Genomic Profiling in Late Stage Cancer Real-World Setting Across Belgium
February 4, 2021 -- Today, Illumina, Inc. (NASDAQ:ILMN) announced an agreement with the Belgian Society of Medical Oncology (BSMO) which is running a new national pilot to evaluate the use of
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended January 3, 2021.
Fourth
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS AND RELEASES 5-YEAR PIPELINE METRICS
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter 2020 and full-year 2020, raised 2021 guidance(4) for Adjusted diluted EPS(2) and provided 2021 financial guidance(4) for other